AstraZeneca to acquire EsoBiotec to advance cell therapy ambition Acquisition includes world-leading in vivo delivery platform with potential to transform cell therapy AstraZeneca has ...

AstraZeneca PLC (NASDAQ:AZN – Get Free Report) has been given an average recommendation of “Buy” by the ten ratings firms that are currently covering the company, Marketbeat.com reports. One equities ...

Today we will run through one way of estimating the intrinsic value of AstraZeneca PLC (LON:AZN ... We generally believe that a company's value is the present value of all of the cash it will ...

AstraZeneca PLC ADR closed 13.33% below its 52-week high of $87.68, which the company achieved on August 30th.

AstraZeneca PLC ADR closed 11.89% below its 52-week high of $87.68, which the company reached on August 30th.

AstraZeneca PLC (NASDAQ:AZN) is a biopharmaceutical company that explores, develops, manufactures, and commercializes prescription medicines. It supplies its products and services to specialty and ...

AstraZeneca PLC beat Q4 and full-year 2024 earnings estimates, with significant revenue and EPS growth, and forecasts further growth in 2025 despite China-related setbacks. The company faces ...

AstraZeneca PLC (NASDAQ:AZN) is a biopharmaceutical company that discovers, develops, and manufacturers prescription medicine. The one-month return of AstraZeneca PLC (NASDAQ:AZN) was 7.59% ...

We recently published a list of 10 Best Weight Loss Drug Stocks to Buy According to Analysts. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against other ...

news outlets reported that a fraud investigation linked to AstraZeneca had expanded to several Chinese government agencies, implicating dozens of senior executives at the Company. On this news, ...

AstraZeneca PLC (LSE:LON:AZN) has reported that Pascal Soriot, the company’s Chief Executive Officer, acquired 89,962 ordinary shares following the vesting of a performance-based award on Monday.